SPI Infoamtion

1. Analyst View

2. Research Methodology

3. Market Drivers
　　　3.1 Increasing Prevalence of Lifestyle Diseases
　　　3.2 Government Incentives Program
　　　3.3 High Affordability

4. German Pharmaceutical Industry Performance
　　　4.1 Market Size and Growth
　　　4.2 By Type
　　　　　　4.2.1 Branded Drugs
　　　　　　4.2.2 Generic Drugs
　　　4.3 Domestic Consumption and Export

5. Latest Industry Trends

6. Government Regulations and Initiatives

7. Competitive Landscape
　　　7.1 Industry Structure
　　　7.2 Key M&As
　　　7.3 Key Players
　　　　　　7.3.1 Bayer Schering Pharma
　　　　　　7.3.2 Pfizer Inc.
　　　　　　7.3.3 Boehringer Ingelheim
　　　　　　7.3.4 Abbott Laboratories
　　　　　　7.3.5 Novartis

List of Figures:
Figure 3-1: Leading Causes of Death (%), 2009
Figure 4-1: Pharmaceutical Market (Billion Euro), 2008-2012
Figure 4-2: Branded Drugs Market (Billion Euro), 2008-2012
Figure 4-3: Generic Drugs Market (Billion Euro), 2008-2012
Figure 4-4: Share of Branded and Generic Drugs in Pharmaceutical Market (Value Terms), 2009
Figure 4-5: Share of Branded and Generic Drugs in Pharmaceutical Market (Volume Terms), 2009
Figure 4-6: Share of Export in Total Pharmaceutical Market (2009)

List of Tables:
Table 7-1: Recent M&As in Pharmaceutical Market
Table 7-2: Bayer Schering Pharma - Strengths & Weaknesses
Table 7-3: Pfizer Inc. - Strengths & Weaknesses
Table 7-4: Boehringer Ingelheim - Strengths & Weaknesses
Table 7-5: Abbott Laboratories - Strengths & Weaknesses
Table 7-6: Novartis - Strengths & Weaknesses